MedTrace Logo

A Study to Evaluate the Safety and Efficacy of Max-40279 and Toripalimab in Patients With Advanced Solid Tumors

NCT05369286 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2022-05-11

No results posted yet for this study

Summary

This include two parts, part 1 is a dose escalation study and part 2 is a dose expansion study.

Conditions

Interventions

DRUG

"MAX-40279-01" and "Toripalimab"

"MAX-40279-01"combined with "Toripalimab"

Sponsors & Collaborators

  • Maxinovel Pty., Ltd.

    lead INDUSTRY

Principal Investigators

  • xiangen MD Lu, Ph.D · Institute of The Sixth Affiliated Hospital Sun Yat-sen University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-11
Primary Completion
2023-05-31
Completion
2023-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05369286 on ClinicalTrials.gov